MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
Status:
Active, not recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate
the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line
therapy to patients with RAS (Rat sarcoma)-mutant mCRC (Metastatic colorectal cancer)
diagnosis who convert to RAS wild-type using monitoring of the RAS mutation status by liquid
biopsy.